A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections

Front Immunol. 2021 Jan 21;11:612269. doi: 10.3389/fimmu.2020.612269. eCollection 2020.


Recurrent urinary tract infections (RUTIs) and recurrent vulvovaginal candidiasis (RVVCs) represent major healthcare problems with high socio-economic impact worldwide. Antibiotic and antifungal prophylaxis remain the gold standard treatments for RUTIs and RVVCs, contributing to the massive rise of antimicrobial resistance, microbiota alterations and co-infections. Therefore, the development of novel vaccine strategies for these infections are sorely needed. The sublingual heat-inactivated polyvalent bacterial vaccine MV140 shows clinical efficacy for the prevention of RUTIs and promotes Th1/Th17 and IL-10 immune responses. V132 is a sublingual preparation of heat-inactivated Candida albicans developed against RVVCs. A vaccine formulation combining both MV140 and V132 might well represent a suitable approach for concomitant genitourinary tract infections (GUTIs), but detailed mechanistic preclinical studies are still needed. Herein, we showed that the combination of MV140 and V132 imprints human dendritic cells (DCs) with the capacity to polarize potent IFN-γ- and IL-17A-producing T cells and FOXP3+ regulatory T (Treg) cells. MV140/V132 activates mitogen-activated protein kinases (MAPK)-, nuclear factor-κB (NF-κB)- and mammalian target of rapamycin (mTOR)-mediated signaling pathways in human DCs. MV140/V132 also promotes metabolic and epigenetic reprogramming in human DCs, which are key molecular mechanisms involved in the induction of innate trained immunity. Splenocytes from mice sublingually immunized with MV140/V132 display enhanced proliferative responses of CD4+ T cells not only upon in vitro stimulation with the related antigens contained in the vaccine formulation but also upon stimulation with phytohaemagglutinin. Additionally, in vivo sublingual immunization with MV140/V132 induces the generation of IgG and IgA antibodies against all the components contained in the vaccine formulation. We uncover immunological mechanisms underlying the potential mode of action of a combination of MV140 and V132 as a novel promising trained immunity-based vaccine (TIbV) for GUTIs.

Keywords: candida albicans V132; dendritic cells; polybacterial preparation MV140; recurrent urinary tract infections (RUTIs); recurrent vulvovaginal candidiasis (RVVCs); trained immunity-based vaccines (TIbVs).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Bacterial / administration & dosage*
  • Antigens, Bacterial / immunology
  • Antigens, Fungal / administration & dosage*
  • Antigens, Fungal / immunology
  • Bacterial Infections / immunology
  • Bacterial Infections / metabolism
  • Bacterial Infections / microbiology
  • Bacterial Infections / prevention & control*
  • Bacterial Vaccines / administration & dosage*
  • Bacterial Vaccines / immunology
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • Candidiasis, Vulvovaginal / immunology
  • Candidiasis, Vulvovaginal / metabolism
  • Candidiasis, Vulvovaginal / microbiology
  • Candidiasis, Vulvovaginal / therapy*
  • Cells, Cultured
  • Coculture Techniques
  • Cytokines / metabolism
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology
  • Female
  • Fungal Vaccines / administration & dosage*
  • Fungal Vaccines / immunology
  • Humans
  • Lymphocyte Activation / drug effects
  • Mice, Inbred BALB C
  • Phenotype
  • Urinary Tract Infections / immunology
  • Urinary Tract Infections / metabolism
  • Urinary Tract Infections / microbiology
  • Urinary Tract Infections / prevention & control*
  • Vaccination
  • Vaccines, Combined / administration & dosage*
  • Vaccines, Combined / immunology


  • Antigens, Bacterial
  • Antigens, Fungal
  • Bacterial Vaccines
  • Cytokines
  • Fungal Vaccines
  • Vaccines, Combined